More than 20 years into proteomics quest, SomaLogic keeps adding investors as it nears a potential public offering
In the world of venture capital, investors are constantly looking for the next best thing — but sometimes a good idea takes time to develop. Take SomaLogic, for example: More than two decades into its life, the biotech is bagging more and more investor cash —and a public offering could be on the close horizon.
A month after closing a $121 million Series A, proteomics-focused SomaLogic is adding another $81 million to the round — becoming, as CEO Roy Smythe joked, “maybe the only biotech company in the history of this industry that’s having its Series A at age 21.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.